Remove 2019 Remove Data Remove Epilepsy Remove Medicine
article thumbnail

NHS To Launch Its First Evidence-Based Cannabis Patient Data Registry This Week – Cannabis Business Executive

SpeedWeed

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.

Data 52
article thumbnail

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Cannabis Law Report

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

States That Restrict MMJ Access Are Interfering With Patients’ Rights, Study Shows

Veriheal

As medicinal and recreational cannabis legalization continues to sweep across the United States, a recent study paints a concerning portrait of many states denying or restricting medical marijuana (MMJ) access. Furthermore, Nugg MD’s data shows just how vital MMJ access has become in modern society’s health landscape.

Access 98
article thumbnail

THC Provides More Symptom Relief Than CBD, According To New Study

MassRoots

Cannabidiol ( CBD ), the non-psychoactive cannabinoid praised for medicinal powers like reducing the severity and frequency of seizures in children suffering from rare and otherwise untreatable forms of epilepsy, may not be the most medically beneficial molecule found in cannabis, according to new data. Data Tracking.

THC 111
article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m.

article thumbnail

Article: Japanese health ministry mulls legalizing marijuana for medical use

Cannabis Law Report

The move comes as the ministry in June 2021 compiled a report recommending that the government allow the use of drugs that contain substances of marijuana to treat refractory epilepsy as the United States and other countries have approved such medications. This summer, the ministry plans to draft proposals to revise the Cannabis Control Law.

article thumbnail

Japan is Poised to Legalize Medical Marijuana

Veriheal

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. 124’—the use and application of medicines manufactured from “marijuana” to any person are currently prohibited.